Document is current

Any future updates will be listed below

Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib

Crossref DOI link: https://doi.org/10.1038/s41523-025-00726-x

Published Online: 2025-02-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark